BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34870568)

  • 1. Underutilisation of prophylactic G-CSF in breast cancer patients receiving adjuvant docetaxel/cyclophosphamide chemotherapy.
    Ku M; Je NK
    J Chemother; 2022 Dec; 34(8):534-542. PubMed ID: 34870568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Febrile neutropenia and role of prophylactic granulocyte colony-stimulating factor in docetaxel and cyclophosphamide chemotherapy for breast cancer.
    Kimura Y; Sasada S; Emi A; Masumoto N; Kadoya T; Okada M
    Support Care Cancer; 2021 Jul; 29(7):3507-3512. PubMed ID: 33146835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of primary granulocyte-colony stimulating factor prophylaxis on neutropenic toxicity and chemotherapy dose delivery in Chinese patients with breast cancer who received adjuvant docetaxel plus cyclophosphamide chemotherapy: a retrospective cohort study.
    Kwok CCH; Wong WH; Chan LL; Wong SPY; Wang F; Wong MCS; Tse SLA
    Hong Kong Med J; 2022 Dec; 28(6):438-446. PubMed ID: 36261264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Outcomes and Cost-effectiveness of Primary Prophylaxis of Febrile Neutropenia During Adjuvant Docetaxel and Cyclophosphamide Chemotherapy for Breast Cancer.
    Yu JL; Chan K; Kurin M; Pasetka M; Kiss A; Sridhar SS; Warner E
    Breast J; 2015; 21(6):658-64. PubMed ID: 26387577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy.
    Chan A; Fu WH; Shih V; Coyuco JC; Tan SH; Ng R
    Support Care Cancer; 2011 Apr; 19(4):497-504. PubMed ID: 20232087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
    Skedgel C; Rayson D; Younis T
    Support Care Cancer; 2016 Jan; 24(1):387-394. PubMed ID: 26081595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of granulocyte-colony stimulating factor on docetaxel-induced febrile neutropenia in patients with breast cancer.
    Zekri J; Nawaz A; Rasool H; Ahmad I; Abdel Rahman H; Dada R; Abdelghany EM; Farag K; Ibrahim RB; Deibas MY; Kamel MK; Allithy A
    J Oncol Pharm Pract; 2022 Dec; 28(8):1681-1686. PubMed ID: 34342555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis.
    Do T; Medhekar R; Bhat R; Chen H; Niravath P; Trivedi MV
    Breast Cancer Res Treat; 2015 Oct; 153(3):591-7. PubMed ID: 26337685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia.
    Clemons M; Fergusson D; Joy AA; Thavorn K; Meza-Junco J; Hiller JP; Mackey J; Ng T; Zhu X; Ibrahim MFK; Sienkiewicz M; Saunders D; Vandermeer L; Pond G; Basulaiman B; Awan A; Pitre L; Nixon NA; Hutton B; Hilton JF;
    Breast; 2021 Aug; 58():42-49. PubMed ID: 33901921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
    Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
    Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer.
    Suzuki K; Sasada S; Kimura Y; Emi A; Kadoya T; Okada M
    Anticancer Res; 2022 Dec; 42(12):5945-5949. PubMed ID: 36456134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Febrile neutropenia incidence and the variable toxicity profile between brand and generic docetaxel in the adjuvant treatment of breast cancer with docetaxel and cyclophosphamide regimen.
    Tarcha FV; Baccarin ALC; Barros LADR; Alencar EBA; Del Giglio A; Cruz FJSM
    Einstein (Sao Paulo); 2023; 21():eAO0486. PubMed ID: 38126660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-World Impact of Prophylactic Growth Factor Use on Timing of Febrile Neutropenia and Infection After High-Risk Chemotherapy.
    Blayney DW; Kuderer NM; Cummings Joyner AK; Jarvis J; Nunag D; Wells J; Huang L; Mohanlal R; Lyman GH
    J Natl Compr Canc Netw; 2023 Sep; 21(9):945-950.e16. PubMed ID: 37673111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer--further observations from the IMPACT solid study.
    Mäenpää J; Varthalitis I; Erdkamp F; Trojan A; Krzemieniecki K; Lindman H; Bendall K; Vogl FD; Verma S
    Breast; 2016 Feb; 25():27-33. PubMed ID: 26801413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study.
    Sakurada T; Bando S; Zamami Y; Takechi K; Chuma M; Goda M; Kirino Y; Nakamura T; Teraoka K; Morimoto M; Tangoku A; Ishizawa K
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1107-1114. PubMed ID: 31502114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the Incidence of Febrile Neutropenia in Doxorubicin/Cyclophosphamide(AC)and Docetaxel/Cyclophosphamide(TC) Perioperative Chemotherapies for Primary Breast Cancer].
    Nohara Y; Ono S; Tanaka M; Yoshinaga Y; Ito T; Yamashita S; Iwasaki A
    Gan To Kagaku Ryoho; 2020 Nov; 47(11):1589-1591. PubMed ID: 33268733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of febrile neutropenia in early stage breast cancer patients receiving adjuvant FEC-D treatment.
    Assi H; Murray J; Boyle L; Rayson D
    Support Care Cancer; 2014 Dec; 22(12):3227-34. PubMed ID: 24996828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
    Agiro A; Ma Q; Acheson AK; Wu SJ; Patt DA; Barron JJ; Malin JL; Rosenberg A; Schilsky RL; Lyman GH
    J Clin Oncol; 2016 Nov; 34(32):3872-3879. PubMed ID: 27646945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles.
    van Dooijeweert C; van der Wall E; Baas IO
    Neth J Med; 2019 Dec; 77(9):310-316. PubMed ID: 31814585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).
    Clemons M; Mazzarello S; Hilton J; Joy A; Price-Hiller J; Zhu X; Verma S; Kehoe A; Ibrahim MF; Sienkiewicz M; Stober C; Vandermeer L; Hutton B; Mallick R; Fergusson D
    Support Care Cancer; 2019 Apr; 27(4):1345-1354. PubMed ID: 30099602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.